MYX 2.23% $4.38 mayne pharma group limited

Quantifying downside risks, page-3

  1. 6,633 Posts.
    lightbulb Created with Sketch. 615
    I dont understand the industry as well as i would like, but my understanding is that Mayne is focused on the US specifically because drugs are so much more expensive their than anywhere else. It does sell/manufacture to other countries as well, but the focus of capital is the US.

    If the US did fix their health system to be like normal countries i expect it would hurt a lot, i dont expect Trump to fix anything, but he could still cause damage to the industry by trying, it is a risk.

    From an ethics point of view, participating in the market by introducing generics (which are cheaper) can only help, and i havent seen anything to suggest that Mayne uses extreme pricing like the owners of the Epi-Pen.

    Mayne is a significant shareholder in Hedgepath which has a trialling a drug which targets some types of cancer. They are building manufacturing plant in US, and also makes a fair bit from lab services, its not a company just sitting back exploiting IP, they do real work as well.
    Last edited by bug1: 21/06/17
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
(20min delay)
Last
$4.38
Change
-0.100(2.23%)
Mkt cap ! $372.6M
Open High Low Value Volume
$4.45 $4.53 $4.38 $514.8K 116.0K

Buyers (Bids)

No. Vol. Price($)
1 4744 $4.38
 

Sellers (Offers)

Price($) Vol. No.
$4.40 168 1
View Market Depth
Last trade - 16.10pm 05/07/2024 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.